Search Results - "BRUNA, Jordi"

Chemotherapy-induced peripheral neurotoxicity (CIPN): An update by Argyriou, Andreas A, Bruna, Jordi, Marmiroli, Paola, Cavaletti, Guido

“…Highlights ► We revise the current knowledge in chemotherapy-induced peripheral neurotoxicity. ► Several effective antineoplastic drugs are harmful to…”
Get full text

Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics by Argyriou, Andreas A., Bruna, Jordi, Genazzani, Armando A., Cavaletti, Guido

“…Key Points Peripheral neurotoxicity is potentially permanent and ranks among the most common non-haematological adverse effects of chemotherapy Identifying…”
Get full text

Chemobrain: A systematic review of structural and functional neuroimaging studies by SIMO, Marta, RIFA-ROS, Xavier, RODRIGUEZ-FORNELLS, Antoni, BRUNA, Jordi

“…Nowadays, chemotherapy-induced cognitive impairment or 'chemobrain' is a well-established clinical syndrome, consisting of moderate to subtle cognitive changes…”
Get full text

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma by Garcia-Ruiz, Alonso, Naval-Baudin, Pablo, Ligero, Marta, Pons-Escoda, Albert, Bruna, Jordi, Plans, Gerard, Calvo, Nahum, Cos, Monica, Majós, Carles, Perez-Lopez, Raquel

“…Glioblastoma is the most common primary brain tumor. Standard therapy consists of maximum safe resection combined with adjuvant radiochemotherapy followed by…”
Get full text

Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment by Psimaras, Dimitri, Velasco, Roser, Birzu, Cristina, Tamburin, Stefano, Lustberg, Maryam, Bruna, Jordi, Argyriou, Andreas A.

“…Immune checkpoint inhibitors (ICIs) are increasingly used and are becoming the standard of care in the treatment of various tumor types. Despite the favorable…”
Get full text

Taxane-Induced Peripheral Neurotoxicity by Velasco, Roser, Bruna, Jordi

“…Taxane-derived agents are chemotherapy drugs widely employed in cancer treatment. Among them, paclitaxel and docetaxel are most commonly administered, but…”
Get full text

Clinical pattern and associations of oxaliplatin acute neurotoxicity by Argyriou, Andreas A., Cavaletti, Guido, Briani, Chiara, Velasco, Roser, Bruna, Jordi, Campagnolo, Marta, Alberti, Paola, Bergamo, Francesca, Cortinovis, Diego, Cazzaniga, Marina, Santos, Cristina, Papadimitriou, Konstantinos, Kalofonos, Haralabos P.

“…BACKGROUND: The objective of the current prospective, multicenter, international study was to trace the incidence and severity of acute oxaliplatin‐induced…”
Get full text

Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study by Argyriou, Andreas A., Karteri, Sofia, Bruna, Jordi, Mariotto, Sara, Simo, Marta, Velissaris, Dimitrios, Kalofonou, Foteini, Cavaletti, Guido, Ferrari, Sergio, Kalofonos, Haralabos P.

“…Objective To prospectively assess the utility of serum neurofilament light chain (sNfL) levels in identifying the risk to develop chemotherapy-induced…”
Get full text

Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis by Pons-Escoda, Albert, Garcia-Ruiz, Alonso, Naval-Baudin, Pablo, Grussu, Francesco, Fernandez, Juan Jose Sanchez, Simo, Angels Camins, Sarro, Noemi Vidal, Fernandez-Coello, Alejandro, Bruna, Jordi, Cos, Monica, Perez-Lopez, Raquel, Majos, Carles

“…Objective Standard DSC-PWI analyses are based on concrete parameters and values, but an approach that contemplates all points in the time-intensity curves and…”
Get full text

Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity by Argyriou, Andreas A., Bruna, Jordi, Anastopoulou, Garifallia G., Velasco, Roser, Litsardopoulos, Pantelis, Kalofonos, Haralabos P.

“…Aim To identify the risk factors of falls in a well-characterized cohort of cancer patients with chemotherapy-induced peripheral neurotoxicity (CIPN). Patients…”
Get full text

Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors by Vilariño, Noelia, Bruna, Jordi, Kalofonou, Foteini, Anastopoulou, Garifallia G, Argyriou, Andreas A

“…Over the last decade, immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several cancer types. ICIs work through the blockage of immune…”
Get full text

Cognitive and brain structural changes in a lung cancer population by Simó, Marta, Root, James C, Vaquero, Lucía, Ripollés, Pablo, Jové, Josep, Ahles, Tim, Navarro, Arturo, Cardenal, Felipe, Bruna, Jordi, Rodríguez-Fornells, Antoni

“…No study has examined structural brain changes specifically associated with chemotherapy in a lung cancer population. The aim of this cross-sectional study was…”
Get more information

Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG) by Preusser, Matthias, Silvani, Antonio, Le Rhun, Emilie, Soffietti, Riccardo, Lombardi, Giuseppe, Sepulveda, Juan Manuel, Brandal, Petter, Brazil, Lucy, Bonneville-Levard, Alice, Lorgis, Veronique, Vauleon, Elodie, Bromberg, Jacoline, Erridge, Sara, Cameron, Alison, Lefranc, Florence, Clement, Paul M, Dumont, Sarah, Sanson, Marc, Bronnimann, Charlotte, Balaná, Carmen, Thon, Niklas, Lewis, Joanne, Mair, Maximilian J, Sievers, Philipp, Furtner, Julia, Pichler, Josef, Bruna, Jordi, Ducray, Francois, Reijneveld, Jaap C, Mawrin, Christian, Bendszus, Martin, Marosi, Christine, Golfinopoulos, Vassilis, Coens, Corneel, Gorlia, Thierry, Weller, Michael, Sahm, Felix, Wick, Wolfgang

“…Abstract Background No systemic treatment has been established for meningioma progressing after local therapies. Methods This randomized, multicenter,…”
Get full text

Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer by Griffith, Kathleen A., Zhu, Shijun, Johantgen, Meg, Kessler, Michael D., Renn, Cynthia, Beutler, Andreas S., Kanwar, Rahul, Ambulos, Nicholas, Cavaletti, Guido, Bruna, Jordi, Briani, Chiara, Argyriou, Andreas A., Kalofonos, Haralabos P., Yerges-Armstrong, Laura M., Dorsey, Susan G.

“…Oxaliplatin-induced peripheral neuropathy (OIPN) is a dose-limiting toxicity of oxaliplatin and affects most colorectal cancer patients. OIPN is commonly…”
Get full text

Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature by Izquierdo, Cristina, Velasco, Roser, Vidal, Noemí, Sánchez, Juan José, Argyriou, Andreas A, Besora, Sarah, Graus, Francesc, Bruna, Jordi

“…Primary central nervous system lymphomas may present as diffuse, nonenhancing infiltrative lesions. This rare variant is termed lymphomatosis cerebri (LC). We…”
Get full text

Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study by Argyriou, Andreas A., Cavaletti, Guido, Antonacopoulou, Anna, Genazzani, Armando A., Briani, Chiara, Bruna, Jordi, Terrazzino, Salvatore, Velasco, Roser, Alberti, Paola, Campagnolo, Marta, Lonardi, Sara, Cortinovis, Diego, Cazzaniga, Marina, Santos, Cristina, Psaromyalou, Aikaterini, Angelopoulou, Aikaterini, Kalofonos, Haralabos P.

“…BACKGROUND The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage‐gated sodium channels (SCNAs) genes that…”
Get full text

Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy by Bruna, Jordi, Velasco, Roser

“…Chemotherapy-induced peripheral neuropathy is a very frequent neurological complication in cancer. Oxaliplatin (OXA) is a platinum analogue used as a…”
Get full text

Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice by Bruna, Jordi, Udina, Esther, Alé, Albert, Vilches, Jorge J., Vynckier, Ann, Monbaliu, Johan, Silverman, Lee, Navarro, Xavier

“…Bortezomib, a proteasome inhibitor, is an antineoplastic drug to treat multiple myeloma and mantle cell lymphoma. Its most clinically significant adverse event…”
Get full text

Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma by Bruna, Jordi, Brell, Marta, Ferrer, Isidre, Gimenez-Bonafe, Pepita, Tortosa, Avelina

“…Meningiomas represent the second most common central nervous system neoplasms in adults and account for 26% of all primary brain tumors. Although most are…”
Get full text

Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice by Alé, Albert, Bruna, Jordi, Herrando, Mireia, Navarro, Xavier, Udina, Esther

“…The proteasome inhibitor bortezomib is nowadays first line treatment for multiple myeloma. One of the most significant adverse events is peripheral neuropathy,…”
Get full text